Finally, we raise the problem of external validity and reporting of adverse effects to determine which patients may best benefit from the new intervention. A minimal set of items that must be reported to allow for critical analysis of results of an RCT are in the CONSORT statement checklist,3 which could be useful for both authors and readers.
<A>Can I trust the results?
To evaluate the effect of a treatment, as in many experiments, the best way is to compare two groups --one undergoing the treatment and one not (control group) --to see which has the best outcome. However, for this comparison to be valid and to avoid bias, the groups must be similar at baseline, undergo the same care apart from the treatment under study and be assessed in the same way at the end of the study. A bias is anything that erroneously influences the difference between groups. Specific methods developed to overcome sources of bias in clinical trials are summarized in Figure 1 , which is adapted from Greenhalgh,4 and detailed below.
<Figure 1 here> <B>Were patients randomized and was the randomization concealed?
Randomizing patients between the treatment and control groups increases the probability of obtaining similar patients in the two groups at baseline and thus avoids selection bias.
Random allocation is the only way to ensure no systematic differences between intervention groups in known but also unknown factors that might affect the outcome.
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Proper randomization rests on two equally important elements: generation of the sequence and its implementation.
Adequate generation of the sequence usually involves a random-number table or a computerized random-number generator. Deterministic allocation methods (sometimes called 'quasi-random' methods), such as alternation, date of birth or first letter of name,
are not considered adequate because of their predictability, which allows for the scheduling of participants, and the possible correlation between the item used (e.g. month of birth, first letter of name) and the outcome.
When implementing the sequence of randomization, if the allocation is not concealed before the patient is assigned to a group, all benefits of randomization are lost.
Unconcealed randomization can lead to clinicians scheduling patients so that patients with particular characteristics receive a certain allocation, thereby biasing the allocation.
Kunz et al. reviewed all available evidence of the effect of lack of concealment of allocation and concluded that studies with inadequate allocation concealment resulted in 35--40% larger estimates of treatment effect.5
In the case of indistinguishable treatment and placebo (e.g. same appearance, same schedule of administration, same taste), the care provider and the patient are blinded and the allocation concealment is self-evident: pre-numbered drugs are administered serially by the care provider. In other cases, some approaches that assure adequate concealment schemes are as follows:
<BLF>Centralized randomization (e.g. after patient consent is obtained, the investigator calls a 24-hour free-phone service to obtain the allocation group) or pharmacy-controlled randomization.
<BL>Pre-numbered or coded identical, sealed containers administered serially to participants.
<BL>On-site computer system combined with group assignments in a locked unreadable computer file that can be assessed only after entering the characteristics of an enrolled subject.
<BLL>Sequentially numbered, opaque, sealed envelopes: however, this method has to be monitored diligently to ensure that investigators do not open several envelopes beforehand and then allocate patients to the desired treatment.
Proper randomization increases the probability of obtaining similar groups at baseline and thus prevents selection bias. However, some differences in baseline characteristics between groups may appear because of chance. Important demographic and clinical characteristics for each study group should be described so that readers can assess how comparable the groups were at baseline for the known prognostic factors. The magnitude and direction of the differences are more important than results of significance statistical tests in detecting potential subversion of the randomization. Several large differences all favouring one group would heighten suspicion about the results of the trial.
<B>Were patients, care providers and outcome assessors blinded?
Blinding refers to keeping key people, such as patients, health-care providers (i.e. those administering the treatment), and outcome assessors (i.e. those assessing the main outcome), unaware of the treatment administered.
Although the term 'double blind' implies that neither the care provider nor the patient knows which treatment was received, it is ambiguous in terms of the blinding of other people, including those assessing patient outcomes.6 Authors should state and readers should carefully assess who was blinded (patients, care providers, outcome assessors, or monitors).
Blinding of patients and health-care providers prevents performance bias. This bias can occur if additional therapeutic interventions (i.e. co-interventions) are provided preferentially in one of the comparison groups. Blinding guarantees the same follow-up, the same attention to the patient, and the same 'placebo effect' in the two groups.
Blinding of outcome assessors minimizes the risk of detection bias. This type of bias occurs if patient assignment influences the process of outcome assessment, and it thus depends on both the blinding status of the assessor and the nature of the outcome.
Blinding of outcome assessors is particularly important for subjective outcomes (e.g. In other situations, clinicians and patients cannot be blinded (e.g. surgery, regimen, rehabilitation, or psychotherapy) or blinding seems feasible but cannot be effective (for specificity of adverse effects, such as bradycardia with beta-blockers). In these situations, methods to blind outcome assessors are particularly useful to avoid detection bias.9
These methods rely mainly on a centralized assessment of the main outcome, which is easy to implement for clinical investigations (e.g. laboratory tests or radiography) or clinical events (blinded adjudication committee) but requires more inventive solutions for physician-driven data (such as videotaping, audiotaping or photography of clinical examination).9,10 <B>Was follow-up complete and were patients analysed in the groups to which they were randomized?
If a rigorous trial has been undertaken to avoid all the biases that can affect the results of the study, an incorrect analytical approach can also introduce bias. In a randomized superiority trial, the most robust analytical method that prevents attrition (exclusion) bias is the intention-to-treat analysis (ITT).11 An ITT analysis means that all patients are analysed in the group to which they were initially randomized, even if they 'cross over'
to the other intervention arm, they discontinue the intervention, or they are lost to followup. This analysis is of particular importance because participants who do not comply with the allocated treatment usually do not have the same prognostic factors as those who comply. For per-protocol or on-treatment analysis, the analysis is restricted to participants who fulfil the protocol in terms of eligibility, interventions (treatment received) and outcome assessment. In a treatment-received analysis, patients are analysed according to the treatment they actually received, regardless of the treatment they were originally allocated to receive. Only an ITT analysis ensures that the balance in prognostic factors arising from the randomization is maintained.12 An ITT analysis answers the question 'Which choice of treatment is better for the patient?' and not 'Which treatment received is better for the patient?'. Only the former question can be answered without bias and, moreover, is the most pragmatic in choosing a treatment.
Thus, ITT analysis should be the analysis of choice.
Many authors claim they performed an ITT analysis when in fact they have not: patients are excluded from the analysis if they never received any treatment, they were randomized but ineligible for the study, or they were lost to follow-up or the outcome was not assessed (e.g. arthroscopy not realized). One must check the ITT assumption by looking at the flow chart of the progress of patients through the phases of the trial and comparing the number of patients randomized to the number analysed ( Figure 2 ). For example, in a study comparing three kinds of mattress, patients with low back pain who were randomized but who never used their mattress were not included in analysis. The conclusion was in favour of the water-bed but the risk of attrition bias is high because the rate of dropout was four times as much higher in the water-bed arm than in the two others arms.13 <Figure 2 here>
The only acceptable exclusions from an analysis are, in a strictly double-blinded study, patients who did not receive any treatment; this is usually called modified or quasi ITT analysis. Because patients do not know the treatment they will receive, their exclusion is unlikely to be due to disillusion in the allocation. If the attrition rate is low and is equally distributed between the study arms, the analysis is unlikely to be too biased.
Performing an ITT analysis usually implies choosing a method to handle missing data.
Because missing data may occur for various reasons, including adverse events related to the treatment, the method used for data imputation must be conservative, that is, not favour the treatment group.14 Some studies also report in addition efficacy data for patients willing to continue experimental treatment in follow-up extension studies. These results must be interpreted with caution because they are of course not analysed under the ITT principle.
If a large proportion of patients cross over to the opposite treatment arm or are lost to follow-up, the interpretation of study results is difficult, and neither an ITT nor a per- In addition, readers should be sceptical of studies involving unconventional outcomes not recognized in other studies.
<B>Clinical relevance and surrogate outcomes
To decide whether to apply the study results in clinical practice, one needs evidence that the treatment studied in an RCT improves outcomes that are important to patients. An elevated blood pressure outcome is of minor consequence to the patient, whereas a stroke is of major importance.
Good outcomes that are clinically relevant for the patient are death, length of hospital stay, myocardial infarction, fractures, and quality of life. The length of follow-up has to be consistent with disease evolution. For example, a follow-up of only 1 month is meaningless for a chronic disease. Kyriakidi et al. showed that only 11% of RCTs of systemic sclerosis had a follow-up of more than 1 year. 16
However, these outcomes are usually substituted by 'surrogate' outcomes, usually biological or imaging markers, which are easier to measure and believed to be indirect measures of the clinically relevant outcome. For example, change in bone mineral density is often used as a surrogate outcome to measure the effectiveness of treatments for the prevention of osteoporotic fractures.
As well as being of questionable clinical relevance, surrogate outcomes are often misleading. 17 The effectiveness of the use of sodium fluoride is a good example of a misleading conclusion: the treatment substantially increases bone mineral density but does not prevent fractures.18
Surrogate outcomes are widely used because observing a difference in a surrogate measure requires a much smaller sample size and shorter follow-up than a clinical outcome. Trials designed to observe changes in bone mineral density require only a few hundred participants, whereas those designed to observe a fracture endpoint require many thousands of participants. However, surrogate outcomes are useful in helping guide research at its earliest stages. The alpha level is the chance taken by researchers to make a type I error: incorrectly declaring a difference to be true because of only chance producing the observed state of events. Customarily, the alpha level is set at 0.05, that is, in no more than one in 20 statistical tests will the test show some effect when in fact no effect exists. If more than one statistical test is used, the chance increases of finding at least one test result in the whole experiment that is statistically significant due to only chance and to incorrectly declare a difference or relationship to be true. In five tests, this chance is 22%; in ten, the chance increases to 40%.
For the same reason, when outcomes are assessed at several time points after randomization, the time point of primary interest must also be defined a priori. Other outcomes of interest are secondary outcomes. All secondary outcomes must also be pre-specified and reported, not just those showing a statistically significant difference between groups. Important outcomes must be considered, but a single study must not have too many outcomes. is to 1, the less effective the therapy. In survival analysis, RR is usually computed over a period of time and called a hazard ratio. In some statistical computations, particularly covariate adjustment, the odds ratio (OR) is computed instead of the RR. The OR is the ratio of events to non-events in the intervention group over the ratio of events to nonevents in the control group. An OR can reasonably be interpreted as a RR as long as the outcome event is rare.
For some treatments and conditions, the benefit of a specific treatment, as measured by the RR, remains approximately constant over patient populations at varying baseline risk.20 As a single estimate of treatment effect can be provided for a broad class of patients, RR appears attractive. However, it is often clinically important to consider the baseline (control) risk of an event before recommending treatment because, for a given RR, the expected absolute benefit of treatment could vary considerably as the baseline risk changes. For example, an estimated RR of 50% might be important for patients at moderate to high risk of a particular adverse event. However, for patients with a low probability of an event, the risk reduction might not be sufficient to warrant the toxic effects and cost of treatment.21
Thus, the absolute risk reduction (ARR) could be considered a better measure of treatment effect because it reflects the expected absolute benefit, taking into account the baseline risk of the patient. The ARR is the difference between the proportion of control patients who die and the proportion of treatment patients who die. In our example, the ARR is as follows: A large treatment effect, in the absolute scale, leads to a small number needed to treat. A treatment that leads to one saved life for every 10 patients treated is clearly better than a competing treatment that saves one life for every 50 treated. A correctly specified NNT must always give the comparator, the therapeutic outcome, the duration of treatment necessary to achieve that outcome, the 95% CI and the baseline risk of event without treatment.
<B>Continuous outcome And these suppositions would be right. In fact, these results are consistent with both an RR of 1.38 (i.e. patients given the new treatment might be 38% more likely to die than control patients) and an RR of 0.41 (i.e. patients subsequently receiving the new treatment might have a risk of dying almost 60% less than that of non-treated patients).
In other words, the 95% CI for this RR is (0.41 − 1.38), and one cannot conclude that the treatment is better. If the trial enrolled 1000 patients per group, and the same event rates
were observed, the point estimate of the RR would still be 0.75, but the CI would be (0.59 − 0.91), and then one could conclude that the treatment is better.
What these examples show is that the larger the sample size of a trial, the larger the number of outcome events, and the greater our confidence that the true RR (or any other measure of efficacy) is close to what we have observed. The point estimate --in this case 0.75 --is the one value most likely to represent the true RR. Values farther from the point estimate become less consistent with the observed RR.
When the CI of a ratio contains 1 (or 0 for a difference) the difference is not statistically significant and the result is compatible with no effect.
<C>P value
Many journals require or strongly encourage the use of CIs, and results should not be reported solely as P values.3 Yet CIs are not always reported, and one needs to know how to interpret P values.
Depending on the test used, there are many ways to calculate a P value, but its meaning is always the same. The P value shows how often the results would have occurred by chance if no difference existed between the two groups. In other words, the P value describes the risk of a false-positive conclusion of a difference when, in truth, no difference exists.
The P value reflects the statistical significance of a difference but not its size. A small difference observed with a large sample is more significant statistically than the same difference observed with a small sample. Thus, a difference could be statistically significant but clinically insignificant. The P value tells only if the observed difference is likely to be true (P < 0.05) or only the result of chance (P > 0.05), that is, statistically not significant. A P < 0.05 means that the result would have arisen by chance in less than one occasion in 20; a P > 0.05 means that the CI of the RR does not contain 1.
<B>Clinical significance vs. statistical significance When looking at the results of a study, one must consider two important concepts:
clinical significance and statistical significance. The former addresses the size of the treatment effect and the later its credibility.
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The literature is full of statistically significant but clinically insignificant results. A clinically significant finding would be one clinically useful for a patient. For example, a study might find that a certain medication causes a statistically significant (P < 0.05) decrease in blood pressure of 2 mmHg, but this decrease would not be clinically significant. By contrast, a finding of a statistically significant decrease in blood pressure of 20 mmHg would be more clinically significant.
Statistical significance depends on the size of the difference between the groups and on the number of patients. The P value alone gives no information on the magnitude of the effect. Clinically trivial differences can be statistically significant if the sample size is sufficiently large. Conversely, clinically important differences can be statistically nonsignificant if the sample size is too small, that is, if the study lacks power ( we need to explore the external validity of the result, that is, its validity in other contexts.2 Of course, if the study result is not valid, even for the subjects studied, its applicability to other groups of subjects is irrelevant.
There is no external validity per se. The results of a study will never be relevant to all patients and all settings, but studies should be designed and their results reported so that clinicians can judge to whom the results can reasonably be applied.
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The following criteria must be considered before applying results to patients:28 <BLF>Setting of the trial: country; health-care system; recruitment from primary, secondary or tertiary care; selection of participating centres and clinicians.
<BL>Selection of patients: eligibility and exclusion criteria, 'run-in' or 'washout' period, 'enrichment' strategies, ratio of randomized patients to eligible non-randomized patients. <BL>Blinding is the best way to avoid performance and detection bias. Studies should clearly state who was blinded (care providers, patients, outcome assessors and/or data analysts), except when it is obvious than everyone is blinded (if the two treatments are really indistinguishable).
<BL>Intention-to-treat analysis is the most robust analytical method. All patients are analysed in the group to which they were initially randomized, even if they cross over to the other intervention arm, they discontinued the intervention or they are lost to follow- 
Figure 3
Clinical significance and interpretation of the P value.
